A Novel Development of Sarcoidosis Following COVID-19 Vaccination and a Literature Review.
COVID-19
angiotensin-converting enzyme (ACE)
mRNA vaccine
sarcoidosis
uveitis
Journal
Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241
Informations de publication
Date de publication:
15 Oct 2022
15 Oct 2022
Historique:
pubmed:
10
8
2022
medline:
19
10
2022
entrez:
9
8
2022
Statut:
ppublish
Résumé
BNT162b2 (Pfizer/BioNTech) is a coronavirus disease 2019 (COVID-19) vaccine containing nucleoside-modified messenger RNA encoding the severe acute respiratory syndrome coronavirus 2 spike glycoprotein. Recently, ocular complications of mRNA vaccines have been reported increasingly frequently. However, immunological adverse events due to mRNA vaccines in real-world settings are not fully known. We herein report the novel development of sarcoidosis manifested as uveitis, bilateral hilar lymphadenopathy, angiotensin-converting enzyme elevation, and epithelioid and giant cell granuloma formation in the lung soon after the first BNT162b2 injection and review the current literature, including three reported cases of sarcoid-like reaction following COVID-19 vaccination.
Identifiants
pubmed: 35945009
doi: 10.2169/internalmedicine.0104-22
pmc: PMC9646347
doi:
Substances chimiques
Angiotensins
0
BNT162 Vaccine
0
COVID-19 Vaccines
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3101-3106Références
Eur J Nucl Med Mol Imaging. 2021 Jul;48(8):2661-2662
pubmed: 33876261
Clin Pharmacol Ther. 1981 Aug;30(2):239-45
pubmed: 7249508
Cureus. 2019 Jun 17;11(6):e4920
pubmed: 31423396
Br J Ophthalmol. 2019 Oct;103(10):1418-1422
pubmed: 30798264
Ocul Immunol Inflamm. 2021 Aug 18;29(6):1216-1224
pubmed: 34559576
Eye (Lond). 2020 Dec;34(12):2352-2353
pubmed: 32620843
Nat Rev Drug Discov. 2018 Apr;17(4):261-279
pubmed: 29326426
N Engl J Med. 2021 Feb 18;384(7):643-649
pubmed: 33378605
Nat Rev Immunol. 2021 Apr;21(4):195-197
pubmed: 33674759
Vaccines (Basel). 2021 Apr 29;9(5):
pubmed: 33946748
N Engl J Med. 2021 Sep 9;385(11):1018-1032
pubmed: 34496176
Lancet. 2014 Mar 29;383(9923):1155-67
pubmed: 24090799
Intern Med. 2021;60(2):209-216
pubmed: 33456025
Am J Ophthalmol Case Rep. 2021 Sep;23:101136
pubmed: 34151047
N Engl J Med. 2021 Dec 2;385(23):2132-2139
pubmed: 34614329
Vaccines (Basel). 2021 Nov 11;9(11):
pubmed: 34835244
Clin Rev Allergy Immunol. 2015 Aug;49(1):6-18
pubmed: 25771769
Chest. 2018 Sep;154(3):664-677
pubmed: 29698718
Vaccines (Basel). 2022 Feb 21;10(2):
pubmed: 35214800
Int J Infect Dis. 2021 Sep;110:95-97
pubmed: 34289406
J Ophthalmic Vis Res. 2021 Jul 29;16(3):490-501
pubmed: 34394876
Nat Rev Immunol. 2021 Feb;21(2):73-82
pubmed: 33340022